MOLN.SW
Molecular Partners AG
Price:  
3.26 
CHF
Volume:  
18,095.00
Switzerland | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

MOLN.SW WACC - Weighted Average Cost of Capital

The WACC of Molecular Partners AG (MOLN.SW) is 6.3%.

The Cost of Equity of Molecular Partners AG (MOLN.SW) is 6.25%.
The Cost of Debt of Molecular Partners AG (MOLN.SW) is 6.00%.

Range Selected
Cost of equity 5.00% - 7.50% 6.25%
Tax rate -% - -% -%
Cost of debt 5.00% - 7.00% 6.00%
WACC 5.0% - 7.5% 6.3%
WACC

MOLN.SW WACC calculation

Category Low High
Long-term bond rate 1.0% 1.5%
Equity market risk premium 5.1% 6.1%
Adjusted beta 0.5 0.66
Additional risk adjustments 1.5% 2.0%
Cost of equity 5.00% 7.50%
Tax rate -% -%
Debt/Equity ratio 0.02 0.02
Cost of debt 5.00% 7.00%
After-tax WACC 5.0% 7.5%
Selected WACC 6.3%

MOLN.SW's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for MOLN.SW:

cost_of_equity (6.25%) = risk_free_rate (1.25%) + equity_risk_premium (5.60%) * adjusted_beta (0.5) + risk_adjustments (1.75%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.